Christopher P. Fox

机构：Nottingham University Hospitals NHS Trust, University of Nottingham · ORCID：0000-0002-6322-9254

发表论文 341 篇 · 总被引 8885 次 · h-index 48

代表论文

• Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study (2025 · Journal of Clinical Oncology · 被引 8)
• Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee (2025 · Bone Marrow Transplantation · 被引 4)
• Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma (2026 · Journal of Clinical Oncology · 被引 3)
• Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study (2026 · Blood · 被引 3)
• Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO (2025 · Blood · 被引 3)
• Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups (2025 · Blood · 被引 3)